Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.92 USD
Change Today 0.0001 / 0.01%
Volume 124.9K
As of 8:04 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

H. Craig Dees Ph.D.

Chairman, Chief Executive Officer, Chief Executive Officer of Xantech and Director of Xantech, Provectus Biopharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 15 board members in 1 different organizations across 1 different industries.

See Board Relationships
As of Fiscal Year 2013


Dr. H. Craig Dees, Ph.D., has been the Chief Executive Officer at Provectus Pharmaceuticals, Inc. since it acquired PPI on April 23, 2002. Dr. Dees serves as the Chief Executive Officer of Xantech, a subsidiary of Provectus Pharmaceuticals Inc. Prior to Provectus, from 1997 to 2002 he served as senior member of the management team of Photogen Technologies, Inc. Prior to Photogen, Dr. Dees served as a Group Leader at the Oak Ridge National Laboratory ('ORNL'), and as ...

Read Full Background

Corporate Headquarters*

7327 Oak Ridge Highway
Knoxville, Tennessee 37931

United States

Phone: 866-594-5999
Fax: 866-998-0005

Board Members Memberships*

Chairman, Chief Executive Officer, Chief Executive Officer of Xantech and Director of Xantech


PhD 1984
University of Wisconsin - Madison

Other Affiliations*

Annual Compensation*

Total Annual Compensation$500,000

Stock Options*

All Other Compensation$114,192
Exercised Options43,750
Exercised Options Value$7,000
Exercisable Options4,550,000
Total Value of Options$7,000
Total Number of Options4,593,750

Total Compensation*

Total Annual Cash Compensation$614,192
Total Short Term Compensation$500,000
Other Long Term Compensation$114,192
Total Calculated Compensation$642,654
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PVCT:US $0.92 USD 0.0001


There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROVECTUS BIOPHARMACEUTICA-A, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at